A share price of Plus Therapeutics Inc [PSTV] is currently trading at $0.8, up 4.77%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PSTV shares have gain 35.90% over the last week, with a monthly amount glided 126.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Plus Therapeutics Inc [NASDAQ: PSTV] stock has seen the most recent analyst activity on March 17, 2025, when D. Boral Capital initiated its Buy rating and assigned the stock a price target of $9. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on January 25, 2021, and set its price target to $8. On October 16, 2020, Maxim Group initiated with a Buy rating and assigned a price target of $6 on the stock.
Plus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.16 and $2.31. Plus Therapeutics Inc [NASDAQ: PSTV] shares were valued at $0.8 at the most recent close of the market.
Analyzing the PSTV fundamentals
Trailing Twelve Months sales for Plus Therapeutics Inc [NASDAQ:PSTV] were 5.21M which represents -36.85% decline. Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -6.39%, Pretax Profit Margin comes in at -11.6%, and Net Profit Margin reading is -11.6%. To continue investigating profitability, this company’s Return on Assets is posted at -2.25, Equity is 2.39 and Total Capital is -9.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Plus Therapeutics Inc [NASDAQ:PSTV] is 0.99. As well, the Quick Ratio is 0.99, while the Cash Ratio is 0.93. Considering the valuation of this stock, the price to sales ratio is 9.23.
Transactions by insiders
Recent insider trading involved Petersen Greg, Director, that happened on May 15 ’25 when 36666.0 shares were purchased. Director, Hawkins Richard J completed a deal on Sep 13 ’24 to buy 4000.0 shares. Meanwhile, Director Hawkins Richard J bought 6285.0 shares on Sep 12 ’24.
